Isavuconazole as Salvage Therapy for Refractory Pediatric Coccidioidal Meningitis.
Amphotericin B
/ administration & dosage
Antifungal Agents
/ administration & dosage
Child
Coccidioides
Coccidioidomycosis
/ drug therapy
Deoxycholic Acid
/ administration & dosage
Drug Combinations
Humans
Meningitis, Fungal
/ drug therapy
Nitriles
/ therapeutic use
Pyridines
/ therapeutic use
Salvage Therapy
Triazoles
/ therapeutic use
Voriconazole
/ administration & dosage
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
pubmed:
15
12
2020
medline:
25
9
2021
entrez:
14
12
2020
Statut:
ppublish
Résumé
Coccidioidal meningitis remains difficult to treat. The newer triazole, isavuconazole, has demonstrated efficacy in invasive fungal disease with less side effects than other azoles. We describe a case of refractory pediatric coccidioidal meningitis with disease stabilization and improvement on isavuconazole after failing treatment with other antifungal agents.
Identifiants
pubmed: 33315746
pii: 00006454-202103000-00029
doi: 10.1097/INF.0000000000003017
doi:
Substances chimiques
Antifungal Agents
0
Drug Combinations
0
Nitriles
0
Pyridines
0
Triazoles
0
Deoxycholic Acid
005990WHZZ
isavuconazole
60UTO373KE
Amphotericin B
7XU7A7DROE
amphotericin B, deoxycholate drug combination
87687-70-5
Voriconazole
JFU09I87TR
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e128-e131Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Jackson NR, Blair JE, Ampel NM. Central nervous system infections due to coccidioidomycosis. J Fungi (Basel). 2019;5:54.
Galgiani JN, Ampel NM, Blair JE, et al. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis. 2016;63:e112–e146.
Thompson GR 3rd, Rendon A, Ribeiro Dos Santos R, et al. Isavuconazole treatment of cryptococcosis and dimorphic mycoses. Clin Infect Dis. 2016;63:356–362.
Marty FM, Ostrosky-Zeichner L, Cornely OA, et al.; VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16:828–837.
Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist. 2013;6:163–174.
Stevens DA, Shatsky SA. Intrathecal amphotericin in the management of coccidioidal meningitis. Semin Respir Infect. 2001;16:263–269.
Ho J, Fowler P, Heidari A, et al. Intrathecal amphotericin B: a 60-year experience in treating coccidioidal meningitis. Clin Infect Dis. 2017;64:519–524.
Stott KE, Hope WW. Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. J Antimicrob Chemother. 2017;72(suppl_1):i12–i18.
Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387:760–769.
Lamoth F, Mercier T, André P, et al. Isavuconazole brain penetration in cerebral aspergillosis. J Antimicrob Chemother. 2019;74:1751–1753.
Schmitt-Hoffmann AH, Kato K, Townsend R, et al. Tissue distribution and elimination of isavuconazole following single and repeat oral-dose administration of isavuconazonium sulfate to rats. Antimicrob Agents Chemother. 2017;61:e01292–17.
Strenger V, Meinitzer A, Donnerer J, et al. Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B. J Antimicrob Chemother. 2014;69:2522–2526.
Cornu M, Bruno B, Loridant S, et al. Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report. BMC Pharmacol Toxicol. 2018;19:81.
De Leonardis F, Novielli C, Giannico B, et al. Isavuconazole treatment of cerebral and pulmonary aspergillosis in a pediatric patient with acute lymphoblastic leukemia: case report and review of literature. J Pediatr Hematol Oncol. 2020;42:e469–e471.
Ashkenazi-Hoffnung L, Bilavsky E, Levy I, et al. Isavuconazole as successful salvage therapy for mucormycosis in pediatric patients. Pediatr Infect Dis J. 2020;39:718–724.
González GM. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med Mycol. 2009;47:71–76.
Heidari A, Quinlan M, Benjamin DJ, et al. Isavuconazole in the treatment of coccidioidal meningitis. Antimicrob Agents Chemother. 2019;63:e02232–18.
Desai A. Predictions of isavuconazonium sulfate dosage in patients aged 6 months to < 18 years. 2018.IDWeek 2018;